New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:06 EDTMYL, GSKProsonix, Mylan enter licensing deal for generic version of Flixotide, Flovent
Prosonix announced that it has entered into a global licensing agreement with Mylan (MYL) for its leading inhaled respiratory products, PSX1001 and PSX1050. PSX1001 and PSX1050 are being developed as generic versions to GlaxoSmithKline's (GSK) pressurised metered dose inhalers Flixotide and Flovent, respectively. According to IMS Health, Flixotide and Flovent had global brand sales of approximately $1.3B for the 12 months ending Dec. 31, 2013. A first marketing authorisation application for PSX1001 is expected to be submitted in the European Union in 2014.
News For MYL;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 29, 2014
07:26 EDTMYL, GSKInforma Business Information to hold a conference
Subscribe for More Information
September 25, 2014
05:36 EDTGSKGlaxoSmithKline names Philip Hampton Non-Executive Director
Subscribe for More Information
September 24, 2014
10:18 EDTGSKGlaxoSmithKline set to name RBS' Philip Hampton as next chairman, Sky News says
Subscribe for More Information
06:23 EDTMYLExperts see new tax rules not halting inversions, WSJ reports
Subscribe for More Information
September 23, 2014
10:54 EDTMYLStocks, analysts react to Treasury inversion crackdown
Subscribe for More Information
09:13 EDTMYLOn The Fly: Pre-market Movers
Subscribe for More Information
09:09 EDTMYLMylan shares defended at BofA/Merrill
Subscribe for More Information
08:53 EDTMYLInversion regulations look more onerous than expected, says FBR Capital
FBR Capital says the new regulations announced last night by the Treasury and IRS contain appear more onerous than expected. FBR points out the proposed changes remove the ability of inverting companies to make "hopscotch loans" between the foreign and domestic subsidiaries. The firm believes the regulations will not end the practice of inversions, and it still expects completion of already announced deals.
08:29 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
08:07 EDTGSKFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
06:28 EDTMYLTreasury rules may put Mylan deal at risk, says BMO Capital
BMO Capital believes Treasury's new inversion rules may put the tax benefits of Mylan's (MYL) planned acquisition of Abbott's (ABT) established products business at risk. BMO also thinks the rules impact Salix's (SLXP) pending deal for Cosmo Pharmaceuticals, which it feels may help make a deal with Allergan (AGN) more likely.
05:56 EDTMYLTreasury, IRS announce plans to reduce inversion tax benefits
Subscribe for More Information
September 22, 2014
10:15 EDTGSKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:21 EDTGSKEBD Group to hold a conference
Subscribe for More Information
05:27 EDTGSKGlaxoSmithKline upgraded to Buy from Neutral at Goldman
Subscribe for More Information
September 19, 2014
11:25 EDTMYLSenators bring bill requiring companies to settle before inverting
U.S. Senators Sherrod Brown and Dick Durbin announced new legislation requiring corporations to "Pay What You Owe Before You Go" – settling their U.S. tax bill before relocating to a foreign country. "Everyone knows that before you leave a restaurant you have to settle your tab," Brown said. "Corporations shouldn’t get to play by different rules. While it is critical that we reach a long-term solution that reforms our international corporate tax code by implementing a global minimum tax and reducing the statutory tax rate, this bill is an immediate, commonsense measure to ensure businesses settle up before leaving the U.S." Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Allergan (AGN).
05:58 EDTGSKGlaxoSmithKline to pay GBP 297M fine to Chinese government
Subscribe for More Information
September 17, 2014
14:57 EDTGSKProsensa announces commencement of re-dosing of drisapersen
Subscribe for More Information
11:01 EDTMYLActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information
07:39 EDTGSKMorningstar to hold a conference
Management Behind the Moat Conference to be held in Chicago on September 17-18.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use